Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683655 | 0.83 | HTR2B (0.49) | GPR35MAPTALOX15MAPK1HTR2B | |
| SCHEMBL723266 | 0.83 | HTR2B (0.49) | GPR35MAPTALOX15MAPK1HTR2B | |
| SCHEMBL31022775 | 0.83 | GPR35 (0.44) | GPR35MAPTHTR2BNPC1RAB9A | |
| SCHEMBL29244139 | 0.83 | GPR35 (0.44) | GPR35MAPTHTR2BNPC1RAB9A | |
| SCHEMBL1336533 | 0.83 | GPR35 (0.44) | GPR35KMOHTR2BNPC1RAB9A | |
| SCHEMBL31022766 | 0.83 | GPR35 (0.44) | GPR35MAPTALOX15MAPK1HTR2B | |
| SCHEMBL9955345 | 0.83 | GPR35 (0.44) | GPR35MAPTHTR2BSMN1; SMN2 | |
| SCHEMBL5501011 | 0.83 | GPR35 (0.44) | GPR35KMOHTR2BSMN1; SMN2PDE4B | |
| SCHEMBL29244162 | 0.83 | GPR35 (0.44) | GPR35MAPTALOX15MAPK1HTR2B | |
| SCHEMBL5493591 | 0.82 | MAPT (0.46) | GPR35MAPTALOX15MAPK1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290434-A | Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof | 南开大学 | 2024-07-05 | — | — | CN | claimed |
| CN-1835937-B | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2012-07-18 | — | — | CN | claimed |
| CN-118290434-A | Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof | 南开大学 | 2024-07-05 | — | — | CN | disclosed |
| CN-1835937-B | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2012-07-18 | — | — | CN | disclosed |
| EP-1656360-B1 | THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| CN-1835937-A | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2006-09-20 | — | — | CN | disclosed |
| EP-1656360-A1 | THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-17 | — | — | EP | disclosed |
| US-20050014952-A1 | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | JASSEN PHARMACEUTICA N.V. (BE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004113309-A1 | THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014952-A1 | Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | GPR35 76/4885MAPT 1237/4885ALOX15 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.